DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange

/EIN News/ -- BROSSARD, Quebec, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the cross-listing of the Corporation's subordinate common shares on the Frankfurt Stock Exchange ("FWB") under the trading symbol "4D4A". FWB is the largest of Germany’s seven stock exchanges. It facilitates advanced electronic trading, settlement and information systems and enables cross-border trading for international investors.

In addition to the FWB, the Corporation's subordinate common shares are also cross-listed on the OTCQB Exchange in the USA under the symbol DGNOF.

André Larente, president of DIAGNOS stated; “by facilitating trading of the Corporation’s common shares in Europe, we strongly believe that cross-listing on the FWB will be beneficial to all current and future shareholders as it will contribute to increase market liquidity for the common shares of DIAGNOS.”

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

Additional information is available at www.diagnos.ca and www.sedarplus.com.

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:
                    
                    Mr. André Larente, President
                    DIAGNOS Inc.
                    Tel: 450-678-8882 ext. 224
                    alarente@diagnos.com